We are thrilled to announce that Digital Diagnostics was highlighted today by NVIDIA CEO Jensen Huang during his keynote address at the GPU Technology Conference (GTC) 2025. This recognition underscores our commitment to revolutionizing healthcare through advanced artificial intelligence.
During the CEO’s keynote address, NVIDIA highlighted how “tokens can see disease before it takes hold” and specifically recognized Digital Diagnostics as a leader in autonomous AI diagnostics. This mention recognizes not only our technological advancements but also our dedication to improving patient outcomes.
Clinical Validation of LumineticsCore™
Our flagship product, LumineticsCore®, is the first FDA-cleared autonomous AI diagnostic system designed to detect diabetic retinopathy at the point-of-care. In a pivotal clinical trial, LumineticsCore demonstrated high diagnostic accuracy, effectively identifying patients with diabetic retinopathy and reducing unnecessary specialist visits by 91%, allowing for patients with referrable levels of disease to access specialist treatment and ongoing follow-up care in a timely manner.
Our Journey with NVIDIA
Our collaboration with NVIDIA has been instrumental in accelerating the development and deployment of our AI solutions. We leverage NVIDIA’s state-of-the-art computing platforms to support the speed and accuracy of our diagnostic tools to help ensure healthcare providers can deliver timely and precise care.
Impact on Patient Care
By integrating LumineticsCore into primary care settings, we have significantly improved early detection rates of diabetic retinopathy, a leading cause of blindness. For instance, OSF HealthCare reported that within the first six months of implementation, 28% of patients with diabetes tested positive for diabetic retinopathy. This early detection allows for timely intervention, potentially preventing vision loss in these patients.
Looking Ahead
The acknowledgment at GTC 2025 inspires us to continue our mission of transforming healthcare through ethically founded AI diagnostic systems. We remain dedicated to improving patient outcomes and expanding access to quality healthcare globally.
Thank you for being a part of the Digital Diagnostics community.